Novartis Diovan Split Committee Vote Gives FDA Latitude In CHF Approval
Executive Summary
A split committee vote on whether to approve Novartis' Diovan for treatment of congestive heart failure gives FDA's cardio-renal division considerable latitude on approvability, Director Ray Lipicky, MD, suggested at the drug's Oct. 11 review.
You may also be interested in...
Atacand Approval Provides Alternative To ACE Inhibitors For Heart Failure
AstraZeneca's angiotensin receptor blocker Atacand can be used as an alternative to angiotensin-converting enzyme inhibitors in reducing risk of cardiovascular mortality and hospitalization in heart failure patients
Atacand Approval Provides Alternative To ACE Inhibitors For Heart Failure
AstraZeneca's angiotensin receptor blocker Atacand can be used as an alternative to angiotensin-converting enzyme inhibitors in reducing risk of cardiovascular mortality and hospitalization in heart failure patients
Novartis Diovan Gets Heart Failure Claim But Is Second Line To ACE Inhibitors
Novartis' Diovan approval for the treatment of heart failure makes the drug the first angiotensin II receptor blocker to carry the indication, but limits it to patients who cannot take ACE inhibitors